The Pfizer Atirmociclib Breast Cancer Research Grants 2027 support investigator-sponsored clinical studies evaluating atirmociclib combinations in HR-positive/HER2-negative metastatic breast cancer and HER2-positive breast cancer. The call also welcomes translational research examining recurrence after adjuvant CDK4/6 inhibitor treatment.
Applicants first submit a research concept; selected teams are invited to develop full proposals. Pfizer has allocated an estimated $8 million across up to six studies.
Eligibility Criteria
- Both institution and PI must be based in an eligible country: Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, UK or US.
- Grants are awarded to organisations.
- PIs must hold an eligible medical, doctoral or advanced healthcare qualification.
- The PI must be employed or contracted by the requesting organisation.
- The organisation must be legally able to receive Pfizer funding.
- Projects must address a specified breast cancer research priority.
- Early-career applicants must provide mentor or collaborator support letters.
Funding Details
- Total pool: $8 million for up to six studies.
- Duration: Three years.
- Individual budgets depend on review.
- Institutional overhead is capped at 28%.
Deadline
- Research concept: January 12, 2027, at 11:59 PM EST.
- Invited proposals: May 7, 2027, provisionally. cdn.vanderbilt.edu